Overview

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Subjects With Warm Autoimmune Hemolytic Anemia (wAIHA)

Status:
Not yet recruiting

Trial end date:
2022-02-15

Target enrollment:

Participant gender:

Summary

This study will evaluate the safety and tolerability of ANX005 in participants with Warm Autoimmune Hemolytic Anemia (wAIHA).

Phase:

Phase 2

Details

Lead Sponsor:

Annexon, Inc.